Research graph
References from Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Drug repurposing for cancer therapy
10.1038/s41392-024-01808-1 · 2024 · External reference
Coumarin derivatives as anticancer agents: mechanistic landscape with an emphasis on breast cancer
10.3390/molecules30214167 · 2025 · External reference
Synthesis, in vitro antitumor activity and molecular mechanism of novel furan derivatives and their precursors
10.2174/1871520620666200424130204 · 2020 · External reference
Harnessing chromone as a versatile scaffold for emerging biological applications: recent advances and medicinal insights
10.1002/tcr.202500073 · 2025 · External reference
Anticancer therapeutic potential of benzofuran scaffolds
10.1039/d3ra01383a · 2023 · External reference
Unveiling the anti-cancer properties of apigenin via targeting different molecular signatures: a review
10.1007/s11033-026-11976-8 · 2026 · External reference
Oxazole derivatives as promising kinase inhibitors: a new era in cancer drug discovery
10.1016/j.bioorg.2026.109979 · 2026 · External reference
N-heterocycles: recent advances in biological applications
10.2174/1570193x19666211231101747 · 2023 · External reference
A review on the medicinal and industrial applications of n-containing heterocycles
10.2174/18741045-v16-e2209010 · 2022 · External reference
Imidazole-based chemosensors: a promising approach for trace copper(II) monitoring
10.1016/j.ica.2025.122983 · 2026 · External reference
Facile one-pot synthesis of imidazole (MID): a highly sensitive turn-off fluorescence probe for mercury (II) ion detection
10.55559/jjbrpac.v3i1.623 · 2026 · External reference
An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013–2023)
10.1021/acs.jmedchem.4c01122 · 2024 · External reference
Recent developments in the antimicrobial potential of some nitrogenous heterocycles and their SAR studies: a review
10.2174/0109298673301266240506083014 · 2025 · External reference
Recent research frontiers of heterocycles as antifungal agents: insights from the past five years
10.1016/j.ejmech.2025.117801 · 2025 · External reference
Recent development of heterocyclic compounds with indazole moiety as potential antiparasitic agents
10.2174/1568026622666220415224139 · 2022 · External reference
Allosteric GABAA receptor modulators—a review on the most recent heterocyclic chemotypes and their synthetic accessibility
10.3390/molecules25040999 · 2020 · External reference
The pyrazole scaffold in anticancer drug discovery: a review of synthetic approaches, structure–activity relationships, and target-based mechanism of action
10.3390/ijms27083403 · 2026 · External reference
Actions of novel angiotensin receptor blocking drugs, bisartans, relevant for COVID-19 therapy: biased agonism at angiotensin receptors and the beneficial effects of neprilysin in the renin angiotensin system
10.3390/molecules27154854 · 2022 · External reference
An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors
10.1007/s11030-024-11016-2 · 2025 · External reference
Triptans in Migraine
10.2165/00003495-200060060-00003 · 2000 · External reference
Quinolines and structurally related heterocycles as antimalarials
10.1016/j.ejmech.2010.04.011 · 2010 · External reference
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
10.1016/j.pharmthera.2019.107447 · 2020 · External reference
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
10.1093/narcan/zcaa002 · 2020 · External reference
The fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2′-deoxyuridine by promoting telomere attrition and mitotic catastrophe
10.1093/narmme/ugag005 · 2026 · External reference
A review on medicinal approaches of novel imatinib derivatives
10.2174/0115680266332163241127114029 · 2025 · External reference
Kinase drug discovery 20 years after imatinib: progress and future directions
10.1038/s41573-021-00195-4 · 2021 · External reference
Application and pharmacological mechanism of methotrexate in rheumatoid arthritis
10.1016/j.biopha.2022.113074 · 2022 · External reference
The pharmacology and clinical use of methotrexate
10.1056/nejm198311033091805 · 1983 · External reference
Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications
2021 · External reference
Exosomes in the chemoresistance of glioma: key point in chemoresistance
10.1111/jcmm.70401 · 2025 · External reference
Exploring tetrazole chemistry: synthetic techniques, structure–activity relationship, and pharmacological insights in antimicrobial and anticancer therapy
10.3389/fchem.2025.1700143 · 2025 · External reference
A new generation of N-heterocyclic carbene (NHC) gold–selenolato complexes as potent anticancer agents: distinct synthetic routes and evaluation in 2D and 3D cancer models
10.1039/d5sc04490a · 2025 · External reference
Synthesis and biological activity of structurally diverse phthalazine derivatives: a systematic review
10.1016/j.bmc.2019.07.050 · 2019 · External reference
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation
10.1039/d4ra03459g · 2024 · External reference
Phthalazine scaffolds in medicinal chemistry: a review of their synthesis, versatility, and pharmacological significance
10.1007/s11030-026-11489-3 · 2026 · External reference
Synthetic and medicinal chemistry of phthalazines: recent developments, opportunities and challenges
10.1016/j.bioorg.2020.104425 · 2020 · External reference
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
10.1073/pnas.0806092105 · 2008 · External reference
Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers
10.1056/nejmoa0900212 · 2009 · External reference
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
10.1016/s1470-2045(14)70228-1 · 2014 · External reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · 2017 · External reference
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · 2018 · External reference
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s1470-2045(17)30469-2 · 2017 · External reference
Olaparib as treatment versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer: phase III SOLO3 study final overall survival results
10.1200/jco.24.00933 · 2025 · External reference
Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer
10.1056/nejmoa1903387 · 2019 · External reference
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies
10.21037/tbcr-25-11 · 2025 · External reference
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency
10.1158/1078-0432.ccr-13-1391 · 2013 · External reference
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers
10.1158/2159-8290.cd-16-1250 · 2017 · External reference
A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)
10.1158/1078-0432.ccr-18-1891 · 2019 · External reference
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
10.1056/nejmoa1802905 · 2018 · External reference
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
10.1016/j.annonc.2020.08.2098 · 2020 · External reference
Small molecules targeting programmed cell death in breast cancer cells
10.3390/ijms22189722 · 2021 · External reference
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
2000 · External reference
Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
10.1054/bjoc.2001.2166 · 2001 · External reference
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
10.1200/jco.2005.09.034 · 2005 · External reference
Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis
10.1593/neo.91864 · 2010 · External reference
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
10.1038/bjc.2011.151 · 2011 · External reference
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
10.1093/annonc/mdr255 · 2012 · External reference
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
10.1007/s10637-013-9978-z · 2013 · External reference
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
10.1007/s11060-010-0390-7 · 2011 · External reference
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
10.1200/jco.2010.29.4496 · 2011 · External reference
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
10.1200/jco.2010.29.5436 · 2011 · External reference
Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies
10.1186/s13065-023-00995-2 · 2023 · External reference
Discovery of a PCAF bromodomain chemical probe
10.1002/anie.201610816 · 2017 · External reference
Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies
10.1016/j.bioorg.2020.103899 · 2020 · External reference
Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: apoptosis-inductive and PCAF-inhibitory effects
10.1016/j.bioorg.2020.104019 · 2020 · External reference
Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors
10.1002/ardp.202000456 · 2021 · External reference
1,2,4-triazole incorporated into polyheterocyclic scaffolds as anti-glioblastoma agents: biological evaluation and molecular modeling studies
10.1016/j.compbiolchem.2025.108771 · 2026 · External reference
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor
10.1021/jm100394y · 2010 · External reference
Hydralazine for essential hypertension
2011 · External reference
Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine
10.1111/j.1476-5381.1995.tb14931.x · 1995 · External reference
Association of hydralazine use with risk of hematologic neoplasms in patients with hypertension: a nationwide population-based cohort study in Taiwan
10.1371/journal.pmed.1004646 · 2025 · External reference
Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells
10.1186/s12885-025-14477-2 · 2025 · External reference
Repurposing the antihypertensive agent hydralazine as an inhibitor of the base excision repair enzyme APE1
10.1021/acs.chemrestox.4c00445 · 2025 · External reference
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
10.1186/1471-2407-5-44 · 2005 · External reference
Azelastine nasal spray in the management of seasonal allergic rhinitis
1994 · External reference
Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial
10.1016/s1081-1206(10)63420-5 · 1996 · External reference
A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis
10.1016/0091-6749(94)90148-1 · 1994 · External reference
Azelastine inhibits triple-negative breast cancer cell viability via an ARF1-dependent mechanism
10.3390/ijms262411849 · 2025 · External reference
The multidirectional effect of azelastine hydrochloride on cervical cancer cells
10.3390/ijms23115890 · 2022 · External reference
The anti-histamine azelastine, identified by computational drug repurposing, inhibits infection by major variants of SARS-CoV-2 in cell cultures and reconstituted human nasal tissue
10.3389/fphar.2022.861295 · 2022 · External reference
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
10.1016/j.virol.2021.05.009 · 2021 · External reference
Anti-chlamydial effects of azelastine hydrochloride and the impact of the histamine H1 receptor on chlamydial development
10.1099/jmm.0.001691 · 2023 · External reference
Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel
2004 · External reference
3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity γ-aminobutyric acid-A benzodiazepine receptor ligands with α2, α3, and α5-subtype binding selectivity over α1
10.1021/jm031020p · 2004 · External reference
GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics
10.2174/156802611795371350 · 2011 · External reference
The plasma–occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, α5IA, is similar in rats and primates
10.1111/j.1476-5381.2009.00216.x · 2009 · External reference
Prodromal dysfunction of α5GABA-A receptor modulated hippocampal ripples occurs prior to neurodegeneration in the TgF344-AD rat model of Alzheimer’s disease
10.1016/j.heliyon.2021.e07895 · 2021 · External reference
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors
10.1002/jmr.2991 · 2022 · External reference
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors
10.1016/j.bioorg.2019.103004 · 2019 · External reference
One-pot synthesis of phthalazines and pyridazino-aromatics: a novel strategy for substituted naphthalenes
10.1021/ol301167q · 2012 · External reference
Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry
10.1016/j.ejmech.2018.10.047 · 2019 · External reference
Anti-HIV activity of stilbene-related heterocyclic compounds
10.1016/j.bmcl.2006.04.087 · 2006 · External reference
An overview of different synthetic routes for the synthesis of phthalazine derivatives
10.9734/jpri/2019/v27i630189 · 2019 · External reference
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives
10.1016/s0960-894x(00)00587-4 · 2001 · External reference
Rational design, synthesis, in vitro, and in-silico studies of pyrazole-phthalazine hybrids as new α-glucosidase inhibitors
10.1038/s41598-025-87258-3 · 2025 · External reference
Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition
10.1080/14756366.2019.1642883 · 2019 · External reference
Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives
10.1016/j.ejmech.2010.05.016 · 2010 · External reference
New convenient one-step synthesis of 4-arylphthalaz-1 -ones
10.1016/s0040-4020(01)91312-2 · 1984 · External reference
A new and convenient synthesis of 3-Aryl-3-hydroxyisoindol-1-ones and their aza analogs
10.1055/s-2001-10804 · 2001 · External reference
Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones
10.1021/jo3000628 · 2012 · External reference
Synthesis of benzo[4,5]imidazo[2,1- a] phthalazines
10.1016/j.tetlet.2003.12.070 · 2004 · External reference
Benzo[4,5]imidazo[2,1-a]phthalazines: I. substituted o-nitrophenylhydrazines in the synthesis of phthalazin-1(2H)-ones
10.1134/s1070428008050175 · 2008 · External reference
Phthalazines and phthalazine hybrids as antimicrobial agents: synthesis and biological evaluation
10.1177/1747519819883840 · 2020 · External reference
Iptycene-derived pyridazines and phthalazines
10.1021/jo702000d · 2007 · External reference
A convenient access to benzo-substituted phthalazines as potential precursors to DNA intercalators
10.1016/s0040-4039(01)01302-8 · 2001 · External reference
Phthalazine derivatives from aromatic aldazines
10.1016/0040-4039(81)80093-7 · 1981 · External reference
Triple aryne-tetrazine reaction enabling rapid access to a new class of polyaromatic heterocycles
10.1039/c5sc01726b · 2015 · External reference
The mechanism of the triple aryne–tetrazine reaction cascade: theory and experiment
10.1039/c8sc01796d · 2018 · External reference
Synthesis of the possible carcinogenic dihydrodiol and diol epoxide of phthalazine
10.1016/j.tet.2004.11.071 · 2005 · External reference
Synthesis of some new phthalazine − piperazine − pyrazole conjugates; in vitro anti-cancer, ADMET and molecular docking studies
10.1002/slct.202204329 · 2023 · External reference
Highlighting multicomponent reactions as an efficient and facile alternative route in the chemical synthesis of organic-based molecules: a tremendous growth in the past 5 years
10.3389/fchem.2024.1469677 · 2024 · External reference
Multicomponent reactions with Meldrum’s acid and isocyanides as a valuable synthetic approach: an update
10.1007/s11030-026-11469-7 · 2026 · External reference
Palladium-catalyzed acylation reactions: a one-pot diversified synthesis of phthalazines, phthalazinones and benzoxazinones
10.1002/ejoc.201800159 · 2018 · External reference
Palladium-catalyzed phthalazinone synthesis using paraformaldehyde as carbon source
10.1021/ol502498y · 2014 · External reference
Palladium-catalyzed synthesis of phthalazinones: efficient carbonylative coupling of 2-bromobenzaldehydes and hydrazines
10.1002/chem.201200267 · 2012 · External reference
Synthesis of tetrahydrophthalazine and phthalamide (phthalimide) derivatives via palladium-catalysed carbonylation of iodoarenes
10.1016/j.tet.2011.09.095 · 2011 · External reference
Microwave assisted palladium-catalyzed synthesis of phthalazinones and pyridopyridazinones
10.1016/j.tetlet.2013.05.006 · 2013 · External reference
Multicomponent synthesis of 4-aminophthalazin-1(2H)-ones by palladium-catalyzed isocyanide insertion
10.1021/jo401131p · 2013 · External reference
Palladium-catalyzed synthesis of 4-aminophthalazin-1(2H)-ones by isocyanide insertion
10.1021/ol202784d · 2011 · External reference
Reaction of 1-nitroso-2-naphthols with α-functionalized ketones and related compounds: the unexpected formation of decarbonylated 2-substituted naphtho[1,2-d][1,3]oxazoles
10.1021/jo3022956 · 2013 · External reference
Visible light amination/smiles cascade: access to phthalazine derivatives
10.1039/c6sc01095d · 2016 · External reference
A convenient metal-free one-pot synthesis of some phthalazine derivatives mediated by 3-picolinic acid
10.1007/s11164-025-05682-6 · 2025 · External reference
Controlled microwave-assisted reactions: a facile synthesis of polyfunctionally substituted phthalazines as dual EGFR and PI3K inhibitors in CNS SNB-75 cell line
10.1016/j.bioorg.2022.105740 · 2022 · External reference
Novel green synthesis of polyfunctionally substituted phthalazines promoted by visible light, DFT studies and molecular docking with antimicrobial and antibiofilm potency
10.1038/s41598-026-47154-w · 2026 · External reference
Green one-pot synthesis of thiazole scaffolds catalyzed by reusable NiFe 2 O 4 nanoparticles: In silico binding affinity and in vitro anticancer activity studies
10.1021/acsomega.4c05587 · 2024 · External reference
An efficient one-pot synthesis of pyridazinones and phthalazinones using HY-zeolite
10.1002/jhet.649 · 2011 · External reference
Design and synthesis of novel phthalazine and benzofuran scaffolds using CoFe2O4@CNSCu nanocatalyst: evaluation of PARP-1 inhibitory activity
10.1016/j.jorganchem.2025.123997 · 2026 · External reference
Discovery of a PCAF bromodomain chemical probe
10.1002/anie.201610816 · ExternalCitation · doi-reference
Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors
10.1002/ardp.202000456 · ExternalCitation · doi-reference
Palladium-catalyzed synthesis of phthalazinones: efficient carbonylative coupling of 2-bromobenzaldehydes and hydrazines
10.1002/chem.201200267 · ExternalCitation · doi-reference
Palladium-catalyzed acylation reactions: a one-pot diversified synthesis of phthalazines, phthalazinones and benzoxazinones
10.1002/ejoc.201800159 · ExternalCitation · doi-reference
An efficient one-pot synthesis of pyridazinones and phthalazinones using HY-zeolite
10.1002/jhet.649 · ExternalCitation · doi-reference
N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors
10.1002/jmr.2991 · ExternalCitation · doi-reference
Synthesis of some new phthalazine − piperazine − pyrazole conjugates; in vitro anti-cancer, ADMET and molecular docking studies
10.1002/slct.202204329 · ExternalCitation · doi-reference
Harnessing chromone as a versatile scaffold for emerging biological applications: recent advances and medicinal insights
10.1002/tcr.202500073 · ExternalCitation · doi-reference
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)
10.1007/s10637-013-9978-z · ExternalCitation · doi-reference
An overview on pharmaceutical applications of phosphodiesterase enzyme 5 (PDE5) inhibitors
10.1007/s11030-024-11016-2 · ExternalCitation · doi-reference
Multicomponent reactions with Meldrum’s acid and isocyanides as a valuable synthetic approach: an update
10.1007/s11030-026-11469-7 · ExternalCitation · doi-reference
Phthalazine scaffolds in medicinal chemistry: a review of their synthesis, versatility, and pharmacological significance
10.1007/s11030-026-11489-3 · ExternalCitation · doi-reference
Unveiling the anti-cancer properties of apigenin via targeting different molecular signatures: a review
10.1007/s11033-026-11976-8 · ExternalCitation · doi-reference
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
10.1007/s11060-010-0390-7 · ExternalCitation · doi-reference
A convenient metal-free one-pot synthesis of some phthalazine derivatives mediated by 3-picolinic acid
10.1007/s11164-025-05682-6 · ExternalCitation · doi-reference
Phthalazine derivatives from aromatic aldazines
10.1016/0040-4039(81)80093-7 · ExternalCitation · doi-reference
A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis
10.1016/0091-6749(94)90148-1 · ExternalCitation · doi-reference
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
10.1016/j.annonc.2020.08.2098 · ExternalCitation · doi-reference
Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors
10.1016/j.bioorg.2019.103004 · ExternalCitation · doi-reference
Novel triazolophthalazine-hydrazone hybrids as potential PCAF inhibitors: design, synthesis, in vitro anticancer evaluation, apoptosis, and molecular docking studies
10.1016/j.bioorg.2020.103899 · ExternalCitation · doi-reference
Design, synthesis, and antitumor activity of novel compounds based on 1,2,4-triazolophthalazine scaffold: apoptosis-inductive and PCAF-inhibitory effects
10.1016/j.bioorg.2020.104019 · ExternalCitation · doi-reference
Synthetic and medicinal chemistry of phthalazines: recent developments, opportunities and challenges
10.1016/j.bioorg.2020.104425 · ExternalCitation · doi-reference
Controlled microwave-assisted reactions: a facile synthesis of polyfunctionally substituted phthalazines as dual EGFR and PI3K inhibitors in CNS SNB-75 cell line
10.1016/j.bioorg.2022.105740 · ExternalCitation · doi-reference
Oxazole derivatives as promising kinase inhibitors: a new era in cancer drug discovery
10.1016/j.bioorg.2026.109979 · ExternalCitation · doi-reference
Application and pharmacological mechanism of methotrexate in rheumatoid arthritis
10.1016/j.biopha.2022.113074 · ExternalCitation · doi-reference
Synthesis and biological activity of structurally diverse phthalazine derivatives: a systematic review
10.1016/j.bmc.2019.07.050 · ExternalCitation · doi-reference
Anti-HIV activity of stilbene-related heterocyclic compounds
10.1016/j.bmcl.2006.04.087 · ExternalCitation · doi-reference
1,2,4-triazole incorporated into polyheterocyclic scaffolds as anti-glioblastoma agents: biological evaluation and molecular modeling studies
10.1016/j.compbiolchem.2025.108771 · ExternalCitation · doi-reference
Quinolines and structurally related heterocycles as antimalarials
10.1016/j.ejmech.2010.04.011 · ExternalCitation · doi-reference
Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives
10.1016/j.ejmech.2010.05.016 · ExternalCitation · doi-reference
Recent advances in the synthesis of phthalazin-1(2H)-one core as a relevant pharmacophore in medicinal chemistry
10.1016/j.ejmech.2018.10.047 · ExternalCitation · doi-reference
Recent research frontiers of heterocycles as antifungal agents: insights from the past five years
10.1016/j.ejmech.2025.117801 · ExternalCitation · doi-reference
Prodromal dysfunction of α5GABA-A receptor modulated hippocampal ripples occurs prior to neurodegeneration in the TgF344-AD rat model of Alzheimer’s disease
10.1016/j.heliyon.2021.e07895 · ExternalCitation · doi-reference
Imidazole-based chemosensors: a promising approach for trace copper(II) monitoring
10.1016/j.ica.2025.122983 · ExternalCitation · doi-reference
Design and synthesis of novel phthalazine and benzofuran scaffolds using CoFe2O4@CNSCu nanocatalyst: evaluation of PARP-1 inhibitory activity
10.1016/j.jorganchem.2025.123997 · ExternalCitation · doi-reference
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
10.1016/j.pharmthera.2019.107447 · ExternalCitation · doi-reference
Synthesis of the possible carcinogenic dihydrodiol and diol epoxide of phthalazine
10.1016/j.tet.2004.11.071 · ExternalCitation · doi-reference
Synthesis of tetrahydrophthalazine and phthalamide (phthalimide) derivatives via palladium-catalysed carbonylation of iodoarenes
10.1016/j.tet.2011.09.095 · ExternalCitation · doi-reference
Synthesis of benzo[4,5]imidazo[2,1- a] phthalazines
10.1016/j.tetlet.2003.12.070 · ExternalCitation · doi-reference
Microwave assisted palladium-catalyzed synthesis of phthalazinones and pyridopyridazinones
10.1016/j.tetlet.2013.05.006 · ExternalCitation · doi-reference
Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
10.1016/j.virol.2021.05.009 · ExternalCitation · doi-reference
New convenient one-step synthesis of 4-arylphthalaz-1 -ones
10.1016/s0040-4020(01)91312-2 · ExternalCitation · doi-reference
A convenient access to benzo-substituted phthalazines as potential precursors to DNA intercalators
10.1016/s0040-4039(01)01302-8 · ExternalCitation · doi-reference
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives
10.1016/s0960-894x(00)00587-4 · ExternalCitation · doi-reference
Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial
10.1016/s1081-1206(10)63420-5 · ExternalCitation · doi-reference
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
10.1016/s1470-2045(14)70228-1 · ExternalCitation · doi-reference
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
10.1016/s1470-2045(17)30469-2 · ExternalCitation · doi-reference
Repurposing the antihypertensive agent hydralazine as an inhibitor of the base excision repair enzyme APE1
10.1021/acs.chemrestox.4c00445 · ExternalCitation · doi-reference
An update on the nitrogen heterocycle compositions and properties of U.S. FDA-approved pharmaceuticals (2013–2023)
10.1021/acs.jmedchem.4c01122 · ExternalCitation · doi-reference
Green one-pot synthesis of thiazole scaffolds catalyzed by reusable NiFe 2 O 4 nanoparticles: In silico binding affinity and in vitro anticancer activity studies
10.1021/acsomega.4c05587 · ExternalCitation · doi-reference
3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity γ-aminobutyric acid-A benzodiazepine receptor ligands with α2, α3, and α5-subtype binding selectivity over α1
10.1021/jm031020p · ExternalCitation · doi-reference
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor
10.1021/jm100394y · ExternalCitation · doi-reference
Synthesis of 4-substituted chlorophthalazines, dihydrobenzoazepinediones, 2-pyrazolylbenzoic acid, and 2-pyrazolylbenzohydrazide via 3-substituted 3-hydroxyisoindolin-1-ones
10.1021/jo3000628 · ExternalCitation · doi-reference
Reaction of 1-nitroso-2-naphthols with α-functionalized ketones and related compounds: the unexpected formation of decarbonylated 2-substituted naphtho[1,2-d][1,3]oxazoles
10.1021/jo3022956 · ExternalCitation · doi-reference
Multicomponent synthesis of 4-aminophthalazin-1(2H)-ones by palladium-catalyzed isocyanide insertion
10.1021/jo401131p · ExternalCitation · doi-reference
Iptycene-derived pyridazines and phthalazines
10.1021/jo702000d · ExternalCitation · doi-reference
Palladium-catalyzed synthesis of 4-aminophthalazin-1(2H)-ones by isocyanide insertion
10.1021/ol202784d · ExternalCitation · doi-reference
One-pot synthesis of phthalazines and pyridazino-aromatics: a novel strategy for substituted naphthalenes
10.1021/ol301167q · ExternalCitation · doi-reference
Palladium-catalyzed phthalazinone synthesis using paraformaldehyde as carbon source
10.1021/ol502498y · ExternalCitation · doi-reference
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
10.1038/bjc.2011.151 · ExternalCitation · doi-reference
Drug repurposing for cancer therapy
10.1038/s41392-024-01808-1 · ExternalCitation · doi-reference
Kinase drug discovery 20 years after imatinib: progress and future directions
10.1038/s41573-021-00195-4 · ExternalCitation · doi-reference
Rational design, synthesis, in vitro, and in-silico studies of pyrazole-phthalazine hybrids as new α-glucosidase inhibitors
10.1038/s41598-025-87258-3 · ExternalCitation · doi-reference
Novel green synthesis of polyfunctionally substituted phthalazines promoted by visible light, DFT studies and molecular docking with antimicrobial and antibiofilm potency
10.1038/s41598-026-47154-w · ExternalCitation · doi-reference
Triple aryne-tetrazine reaction enabling rapid access to a new class of polyaromatic heterocycles
10.1039/c5sc01726b · ExternalCitation · doi-reference
Visible light amination/smiles cascade: access to phthalazine derivatives
10.1039/c6sc01095d · ExternalCitation · doi-reference
The mechanism of the triple aryne–tetrazine reaction cascade: theory and experiment
10.1039/c8sc01796d · ExternalCitation · doi-reference
Anticancer therapeutic potential of benzofuran scaffolds
10.1039/d3ra01383a · ExternalCitation · doi-reference
Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation
10.1039/d4ra03459g · ExternalCitation · doi-reference
A new generation of N-heterocyclic carbene (NHC) gold–selenolato complexes as potent anticancer agents: distinct synthetic routes and evaluation in 2D and 3D cancer models
10.1039/d5sc04490a · ExternalCitation · doi-reference
Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
10.1054/bjoc.2001.2166 · ExternalCitation · doi-reference
A new and convenient synthesis of 3-Aryl-3-hydroxyisoindol-1-ones and their aza analogs
10.1055/s-2001-10804 · ExternalCitation · doi-reference
The pharmacology and clinical use of methotrexate
10.1056/nejm198311033091805 · ExternalCitation · doi-reference
Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers
10.1056/nejmoa0900212 · ExternalCitation · doi-reference
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
10.1056/nejmoa1706450 · ExternalCitation · doi-reference
Talazoparib in patients with advanced breast cancer and a germline BRCA mutation
10.1056/nejmoa1802905 · ExternalCitation · doi-reference
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
10.1056/nejmoa1810858 · ExternalCitation · doi-reference
Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer
10.1056/nejmoa1903387 · ExternalCitation · doi-reference
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
10.1073/pnas.0806092105 · ExternalCitation · doi-reference
Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition
10.1080/14756366.2019.1642883 · ExternalCitation · doi-reference
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
10.1093/annonc/mdr255 · ExternalCitation · doi-reference
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
10.1093/narcan/zcaa002 · ExternalCitation · doi-reference
The fluoropyrimidine polymer CF10 synergizes with 5-ethynyl-2′-deoxyuridine by promoting telomere attrition and mitotic catastrophe
10.1093/narmme/ugag005 · ExternalCitation · doi-reference
Anti-chlamydial effects of azelastine hydrochloride and the impact of the histamine H1 receptor on chlamydial development
10.1099/jmm.0.001691 · ExternalCitation · doi-reference
Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine
10.1111/j.1476-5381.1995.tb14931.x · ExternalCitation · doi-reference
The plasma–occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, α5IA, is similar in rats and primates
10.1111/j.1476-5381.2009.00216.x · ExternalCitation · doi-reference
Exosomes in the chemoresistance of glioma: key point in chemoresistance
10.1111/jcmm.70401 · ExternalCitation · doi-reference
Benzo[4,5]imidazo[2,1-a]phthalazines: I. substituted o-nitrophenylhydrazines in the synthesis of phthalazin-1(2H)-ones
10.1134/s1070428008050175 · ExternalCitation · doi-reference
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency
10.1158/1078-0432.ccr-13-1391 · ExternalCitation · doi-reference
A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)
10.1158/1078-0432.ccr-18-1891 · ExternalCitation · doi-reference
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers
10.1158/2159-8290.cd-16-1250 · ExternalCitation · doi-reference
Phthalazines and phthalazine hybrids as antimicrobial agents: synthesis and biological evaluation
10.1177/1747519819883840 · ExternalCitation · doi-reference
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
10.1186/1471-2407-5-44 · ExternalCitation · doi-reference
Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells
10.1186/s12885-025-14477-2 · ExternalCitation · doi-reference
Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies
10.1186/s13065-023-00995-2 · ExternalCitation · doi-reference
Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
10.1200/jco.2005.09.034 · ExternalCitation · doi-reference
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
10.1200/jco.2010.29.4496 · ExternalCitation · doi-reference
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
10.1200/jco.2010.29.5436 · ExternalCitation · doi-reference
Olaparib as treatment versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer: phase III SOLO3 study final overall survival results
10.1200/jco.24.00933 · ExternalCitation · doi-reference
Association of hydralazine use with risk of hematologic neoplasms in patients with hypertension: a nationwide population-based cohort study in Taiwan
10.1371/journal.pmed.1004646 · ExternalCitation · doi-reference
Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis
10.1593/neo.91864 · ExternalCitation · doi-reference
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies
10.21037/tbcr-25-11 · ExternalCitation · doi-reference
Triptans in Migraine
10.2165/00003495-200060060-00003 · ExternalCitation · doi-reference
Recent developments in the antimicrobial potential of some nitrogenous heterocycles and their SAR studies: a review
10.2174/0109298673301266240506083014 · ExternalCitation · doi-reference
A review on medicinal approaches of novel imatinib derivatives
10.2174/0115680266332163241127114029 · ExternalCitation · doi-reference
GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics
10.2174/156802611795371350 · ExternalCitation · doi-reference
Recent development of heterocyclic compounds with indazole moiety as potential antiparasitic agents
10.2174/1568026622666220415224139 · ExternalCitation · doi-reference
N-heterocycles: recent advances in biological applications
10.2174/1570193x19666211231101747 · ExternalCitation · doi-reference
Synthesis, in vitro antitumor activity and molecular mechanism of novel furan derivatives and their precursors
10.2174/1871520620666200424130204 · ExternalCitation · doi-reference
A review on the medicinal and industrial applications of n-containing heterocycles
10.2174/18741045-v16-e2209010 · ExternalCitation · doi-reference
Highlighting multicomponent reactions as an efficient and facile alternative route in the chemical synthesis of organic-based molecules: a tremendous growth in the past 5 years
10.3389/fchem.2024.1469677 · ExternalCitation · doi-reference
Exploring tetrazole chemistry: synthetic techniques, structure–activity relationship, and pharmacological insights in antimicrobial and anticancer therapy
10.3389/fchem.2025.1700143 · ExternalCitation · doi-reference
The anti-histamine azelastine, identified by computational drug repurposing, inhibits infection by major variants of SARS-CoV-2 in cell cultures and reconstituted human nasal tissue
10.3389/fphar.2022.861295 · ExternalCitation · doi-reference
Small molecules targeting programmed cell death in breast cancer cells
10.3390/ijms22189722 · ExternalCitation · doi-reference
The multidirectional effect of azelastine hydrochloride on cervical cancer cells
10.3390/ijms23115890 · ExternalCitation · doi-reference
Azelastine inhibits triple-negative breast cancer cell viability via an ARF1-dependent mechanism
10.3390/ijms262411849 · ExternalCitation · doi-reference
The pyrazole scaffold in anticancer drug discovery: a review of synthetic approaches, structure–activity relationships, and target-based mechanism of action
10.3390/ijms27083403 · ExternalCitation · doi-reference
Allosteric GABAA receptor modulators—a review on the most recent heterocyclic chemotypes and their synthetic accessibility
10.3390/molecules25040999 · ExternalCitation · doi-reference
Actions of novel angiotensin receptor blocking drugs, bisartans, relevant for COVID-19 therapy: biased agonism at angiotensin receptors and the beneficial effects of neprilysin in the renin angiotensin system
10.3390/molecules27154854 · ExternalCitation · doi-reference
Coumarin derivatives as anticancer agents: mechanistic landscape with an emphasis on breast cancer
10.3390/molecules30214167 · ExternalCitation · doi-reference
Facile one-pot synthesis of imidazole (MID): a highly sensitive turn-off fluorescence probe for mercury (II) ion detection
10.55559/jjbrpac.v3i1.623 · ExternalCitation · doi-reference
An overview of different synthetic routes for the synthesis of phthalazine derivatives
10.9734/jpri/2019/v27i630189 · ExternalCitation · doi-reference
